• Company
• Alecensa prepares to solidify its lead in lung cancer mkt
• by Son, Hyung-Min Feb 23, 2024 05:49am

• Company
• Alteogen expands license agreement with MSD
• by Kim, Jin-Gu Feb 23, 2024 05:49am

• Company
• 2 ADC drugs being discussed for reimb after Enhertu
• by Eo, Yun-Ho Feb 23, 2024 05:49am

• Policy
• Competition intensifies in 3-combo drug mkt for COPD·asthma
• by Lee, Tak-Sun Feb 23, 2024 05:48am

• Policy
• Gov't 'Too soon to price immune-oncology drugs by indication
• by Lee, Jeong-Hwan Feb 22, 2024 05:49am

• Company
• Yuhan ‘confirms the safety and efficacy of its allergy drug
• by Son, Hyung-Min Feb 22, 2024 05:49am

• Company
• Samsung Bioepis starts Global P1T for Keytruda biosimilar
• by Kim, Jin-Gu Feb 22, 2024 05:49am

• Company
• Pfizer’s Zavicefta, sole CRE antibiotic in KOR, gets reimb
• by Son, Hyung-Min Feb 22, 2024 05:49am

• Company
• K-made anticancer drugs Leclaza, Rolontis show sales growth
• by Chon, Seung-Hyun Feb 22, 2024 05:49am

• Policy
• ‘Gavreto’ withdrawn from KOR amid reimb rejection
• by Lee, Hye-Kyung Feb 21, 2024 05:45am